CRISPR-Cas Systems in Bacterial Pathogens: Emerging Tools for Therapeutic Development
Keywords:
CRISPR-Cas systems, Bacterial pathogens, Antibiotic resistance, Gene editing, Therapeutic development, Virulence factorsAbstract
CRISPR-Cas systems have revolutionized the field of microbiology and genetic engineering, providing powerful tools for targeting bacterial pathogens. These adaptive immune mechanisms in bacteria serve not only as a defense against phage infections but also hold immense potential for therapeutic development. This review explores the intricate mechanisms of CRISPR-Cas systems, their classification, and their applications in combating antibiotic resistance and virulence in various bacterial pathogens. We highlight specific case studies demonstrating successful CRISPR interventions in bacteria such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Additionally, we discuss delivery mechanisms for CRISPR components, the challenges of off-target effects, and the ethical considerations surrounding gene editing. With ongoing advancements in CRISPR technology and its integration with other therapeutic approaches, we envision a future where CRISPR-based therapies significantly enhance our ability to manage bacterial infections.
References
1. Barrangou R, Doudna JA. Applications of CRISPR technologies in research and beyond. Nature Biotechnology. 2016; 34(9): 933-941. doi:10.1038/nbt.3650
2. World Health Organization. Antibacterial agents in clinical development. 2017. Available from: https://www.who.int/publications/i/item/antibacterial-agents-in-clinical-development
3. Chen JS, Dagdas YS, Kleinstiver BP, et al. Enhanced proofreading governs CRISPR–Cas9 targeting accuracy. Nature. 2017; 550(7676): 407-410. doi:10.1038/nature24030
4. Kim H, Kim JS. A guide to genome engineering with CRISPR/Cas9. Nature Reviews Genetics. 2014; 15(5): 341-350. doi:10.1038/nrg3737
5. Zhang F, Wen Y, Guo X. CRISPR/Cas9 for genome editing: progress, implications, and challenges. Nature Reviews Molecular Cell Biology. 2020; 21(5): 351-370. doi:10.1038/s41580-020-0227-5
6. Makarova KS, Wolf YI, Iranzo J, et al. An updated evolutionary classification of CRISPR-Cas systems. Nat Rev Microbiol. 2019;17(3):207-211. doi:10.1038/s41579-018-0081-2.
7. Jansen R, van Embden JDA, Gaastra W, et al. Identification of a novel family of phage-related CRISPR-cas systems. Mol Microbiol. 2002;43(6):1575-1585. doi:10.1046/j.1365-2958.2002.02960.x.
8. Doudna JA, Charpentier E. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096. doi:10.1126/science.1258096.
9. Sorek R, Lawrence CM, Wiedenheft B. CRISPR-mediated adaptive immune systems in Bacteria and Archaea. Annu Rev Biophys. 2013;42:575-599. doi:10.1146/annurev-biophys-083012-130302.
10. Tschowri N, Maerkl SJ. Synthetic transcriptional regulators for CRISPR-based genome editing. Nucleic Acids Res. 2019;47(4):1936-1949. doi:10.1093/nar/gky1275.
11. Wang T, Wei J, Zhang M, et al. Targeting antibiotic resistance in Escherichia coli using CRISPR-Cas9 technology. Antibiotics (Basel). 2020;9(10):684. doi:10.3390/antibiotics9100684.
12. Liu Y, Wang C, Yang Y, et al. CRISPR/Cas9-mediated editing of virulence genes in Staphylococcus aureus. Microb Pathog. 2020;138:103821. doi:10.1016/j.micpath.2019.103821.
13. Siu K, Al-Azzam S, Choi K, et al. Targeting Staphylococcus aureus virulence factors using CRISPR technology: A novel strategy to enhance antibacterial effectiveness. Antimicrob Agents Chemother. 2021;65(7)doi:10.1128/AAC.02098-20.
14. Shakeri N, Sadeghi A, Nasr F, et al. CRISPR/Cas9-mediated targeting of antibiotic resistance genes in Escherichia coli. Appl Microbiol Biotechnol. 2020;104(1):69-82. doi:10.1007/s00253-019-10053-3.
15. Xu Y, Liu Y, Zhang L, et al. CRISPR/Cas9-based technology for combating multidrug-resistant Pseudomonas aeruginosa. Microb Drug Resist. 2021;27(1):33-40. doi:10.1089/mdr.2020.0121.
16. Kearns DB, Losick R. Cell population heterogeneity during growth of Bacillus subtilis. Genes Dev. 2003;17(12):1425-1431. doi:10.1101/gad.1102403.
17. Mertens K, De Meyer T, Nuytten N, et al. Bacteriophage-mediated delivery of CRISPR/Cas9 in Escherichia coli. Nucleic Acids Res. 2020;48(12):6820-6831. doi:10.1093/nar/gkaa386.
18. Li S, Liu W, Cheng Z, et al. Development of lipid nanoparticles for CRISPR/Cas9 delivery in vivo. Bioeng Transl Med. 2021;6(3)doi:10.1002/btm2.10216.
19. Tsai SQ, Zheng Z, Sampson TR, et al. Guide RNA optimization for CRISPR-Cas9 mediated gene editing in E. coli. Nucleic Acids Res. 2015;43(12):7881-7891. doi:10.1093/nar/gkv1001.
20. Hsu PD, Lander ES, Zhang F. Development and applications of CRISPR-Cas9 for genome engineering. Cell. 2014;157(6):1262-1278. doi:10.1016/j.cell.2014.05.010.
21. Zhang Y, Bae S, Buhl E, et al. Resistance of Staphylococcus aureus to CRISPR-Cas9 mediated gene editing. Antimicrob Agents Chemother. 2017;61(9)doi:10.1128/AAC.00659-17.
22. Caplan AL, Parent B, Sulmasy DP. The ethics of CRISPR and gene editing. Cambridge Quarterly of Healthcare Ethics. 2015;24(4):347-356. doi:10.1017/S0963180115000166.
23. Gaj T, Guo J, Kato Y, et al. A Comprehensive Review of the Regulatory Framework for CRISPR/Cas9 Gene Editing Technology. Front Bioeng Biotechnol. 2020;8:61. doi:10.3389/fbioe.2020.00061.
24. Jasanoff S. The ethics of emerging technologies: a report from the frontiers of knowledge. Nature. 2021;592(7856):348-350. doi:10.1038/d41586-021-00509-4.
25. Kim S, Kim D, Cho SW, et al. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoprotein. Genome Res. 2014;24(6):1012-1019. doi:10.1101/gr.171322.113.
26. Avila A, Younus A, Schulte R, et al. CRISPR-Cas9 for personalized medicine: a new era in the treatment of bacterial infections. Curr Opin Microbiol. 2020;57:80-86. doi:10.1016/j.mib.2020.07.007.
27. Frieri M, Kumar K, Ozdemir O. Antibiotic resistance. J Infect Public Health. 2017;10(4):369-378. doi:10.1016/j.jiph.2016.08.007.
